AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9778280 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 2 mg twice daily
Number of subjects: 37
Study 9778280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7523607 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (n = 8)
Number of subjects: 33
Study 7523607 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-MOPP (n = 9)
Number of subjects: 33
Study 7523607 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE/MOPP flexitherapy (n = 8)
Number of subjects: 33
Study 7523607 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 33
Study 7523607 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-MOPP and ProMACE/MOPP flexitherapy combined
Number of subjects: 33
Study 7523607 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized disease treatment (MOPP plus radiation)
Number of subjects: 33
Study 3220232 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan (2.5 mg/kg intravenously at a constant rate in 20 min)
Number of subjects: 10
Study 3220232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30548111 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-oriented therapy (cooking)
Number of subjects: 7
Study 30548111 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based activities
Number of subjects: 7
Study 29706047 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g tid for 12 weeks)
Number of subjects: 216
Study 29706047 — intervention group
Group type: COMPARATOR
Intervention: Wuziyanzong Pills (6 g bid for 12 weeks)
Number of subjects: 216
Study 26714371 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise
Number of subjects: 88
Study 26714371 — intervention group
Group type: COMPARATOR
Intervention: Land exercise
Number of subjects: 88
Study 23400750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal taggant (2‐butyl acetate, 2‐pentyl acetate, isopropyl butyrate, or 2‐pentyl butyrate; 30 mg) in hydroxyethylcellulose or tenofovir placebo gel
Number of subjects: 12
Study 23400750 — intervention group
Group type: COMPARATOR
Intervention: Dermal administration of the same formulations
Number of subjects: 12
Study 23400750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal taggant
Number of subjects: 12
Study 20512389 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablets containing bovine lactoferrin and lactoperoxidase
Number of subjects: 15
Study 20512389 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 15
Study 19250310 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U of BoNT‐A
Number of subjects: 0
Study 19250310 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 U of BoNT‐A
Number of subjects: 0
Study 19250310 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 19250310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of BoNT‐A (20 U and 30 U)
Number of subjects: 0
Study 17295590 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.1 mg/kg
Number of subjects: 36
Study 17295590 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 36
Study 17295590 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 14965847 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal maternal and paternal bonding profiles (high care/low overprotection)
Number of subjects: 246
Study 14965847 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal care
Number of subjects: 246
Study 14965847 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal overprotection
Number of subjects: 246
Study 11221825 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous APC variant genotype
Number of subjects: 3580
Study 11221825 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous APC variant genotype diagnosed after age 65
Number of subjects: 3580
Study 11221825 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous APC variant genotype with low-fat diet
Number of subjects: 3580
Study 11221825 — intervention group
Group type: COMPARATOR
Intervention: Control group (homozygote wild type)
Number of subjects: 3580
Study 9621667 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg.kg‐1) with lidocaine (group ML)
Number of subjects: 27
Study 9621667 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg.kg‐1) (group L)
Number of subjects: 27
Study 7921861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 micrograms of intrathecal fentanyl
Number of subjects: 79
Study 7921861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 79
Study 3052813 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 42
Study 3052813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30792007 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP‐XR 300 mg/300 mg
Number of subjects: 504
Study 30792007 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP‐XR 300 mg/100 mg
Number of subjects: 504
Study 30792007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 30107404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fronto-temporal transcranial direct current stimulation (tDCS) with 2-mA, twice-daily sessions for 5 consecutive days.
Number of subjects: 60
Study 30107404 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study 26735919 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour reduction in daily sitting
Number of subjects: 30
Study 26735919 — intervention group
Group type: EXPERIMENTAL
Intervention: accumulating 30 additional brief sit‐to‐stand transitions per day
Number of subjects: 30
Study 26735919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 24473220 — intervention group
Group type: EXPERIMENTAL
Intervention: Private rehabilitation
Number of subjects: 4000
Study 24473220 — intervention group
Group type: COMPARATOR
Intervention: Public rehabilitation
Number of subjects: 4000
Study 22551119 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of 150 ml tomato juice (15 mg lycopene) for 5 weeks
Number of subjects: 15
Study 22551119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tomato juice intake during wash-out period)
Number of subjects: 15
Study 20705564 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Bevacizumab
Number of subjects: 76
Study 17641547 — intervention group
Group type: EXPERIMENTAL
Intervention: r19‐kD protein
Number of subjects: 37
Study 17641547 — intervention group
Group type: EXPERIMENTAL
Intervention: skin prick tests
Number of subjects: 37
Study 17641547 — intervention group
Group type: EXPERIMENTAL
Intervention: r19‐kD protein sIgE ELISAs
Number of subjects: 37
Study 17641547 — intervention group
Group type: COMPARATOR
Intervention: BW sIgE coated allergen particle test
Number of subjects: 37
Study 15761090 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 39 degrees C (T2)
Number of subjects: 12
Study 15761090 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 45 degrees C (T3)
Number of subjects: 12
Study 15761090 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 33 degrees C (T1)
Number of subjects: 12
Study 15761090 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature increase from T1 to T3
Number of subjects: 12
Study 12410473 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (A-P)
Number of subjects: 330
Study 12410473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 10465129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g three times daily
Number of subjects: 148
Study 10465129 — intervention group
Group type: COMPARATOR
Intervention: Cefepime 2 g twice daily
Number of subjects: 148
Study 8591679 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized developmentally oriented care plans
Number of subjects: 40
Study 1693738 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 45
Study 1693738 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 45
Study 1693738 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (added after 8 weeks for uncontrolled patients)
Number of subjects: 45
Study 157076 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg or 400 mg three times daily for 10 days)
Number of subjects: 75
Study 30975539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention (behavioral support and pharmacological aids)
Number of subjects: 526
Study 30975539 — intervention group
Group type: COMPARATOR
Intervention: Usual care (access to local smoking cessation services)
Number of subjects: 526
Study 30975539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention
Number of subjects: 526
Study 28493502 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam 50 mg
Number of subjects: 421
Study 28493502 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam 25 mg
Number of subjects: 421
Study 28493502 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 421
Study 26051566 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 100% lavender essential oil
Number of subjects: 34
Study 26051566 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 34
Study 26051566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with water)
Number of subjects: 34
Study 23343319 — intervention group
Group type: EXPERIMENTAL
Intervention: School nurse-delivered counseling intervention utilizing cognitive-behavioral techniques
Number of subjects: 84
Study 23343319 — intervention group
Group type: COMPARATOR
Intervention: Nurse contact with provision of information
Number of subjects: 84
Study 21366756 — intervention group
Group type: EXPERIMENTAL
Intervention: Family home visiting services for mothers with ID
Number of subjects: 68
Study 21366756 — intervention group
Group type: COMPARATOR
Intervention: Family home visiting services for mothers without ID
Number of subjects: 68
Study 18824040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (30 mg oral dose)
Number of subjects: 19
Study 18824040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17911367 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model of care (all MH/SA services provided at primary care clinics)
Number of subjects: 183
Study 17911367 — intervention group
Group type: COMPARATOR
Intervention: Enhanced referral model of care (all MH/SA services provided at specialized MH clinics)
Number of subjects: 183
Study 17911367 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model of care
Number of subjects: 183
Study 17911367 — intervention group
Group type: COMPARATOR
Intervention: Enhanced referral model of care
Number of subjects: 183
Study 15538933 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH antagonist (N‐Ac‐Tyr(1), D‐Arg(2)) GHRH‐29 (NH(2))
Number of subjects: 20
Study 15538933 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 11288008 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute arthroscopic repair (28 patients; 22 with transglenoid suture, 6 with bone anchor suture fixation)
Number of subjects: 46
Study 11288008 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (18 patients)
Number of subjects: 46
Study 9040547 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of zinc per day for the first 3 days of TPN
Number of subjects: 44
Study 9040547 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of zinc per day for the first 3 days of TPN
Number of subjects: 44
Study 7880665 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective warming using BairHugger and Warm Touch blankets
Number of subjects: 0
Study 7880665 — intervention group
Group type: EXPERIMENTAL
Intervention: BairHugger 500 power unit set at medium setting of 38 degrees C
Number of subjects: 0
Study 2833881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 71
Study 2833881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31597622 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 x 5mg/day)
Number of subjects: 60
Study 30115054 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Physical Activity (DPA) program consisting of 20 minutes of teacher-led DPA for 20 consecutive weeks
Number of subjects: 362
Study 30115054 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practices)
Number of subjects: 362
Study 26890552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 1789
Study 26890552 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1789
Study 25742320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (customised, interactive, automated voice reminders sent weekly)
Number of subjects: 631
Study 25742320 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 631
Study 25742320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 631
Study 22943559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal TFV 1% gel (7-day exposure)
Number of subjects: 18
Study 22943559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal TFV 1% gel (single exposure)
Number of subjects: 18
Study 22943559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal TFV 1% gel (single and 7-day exposure)
Number of subjects: 18
Study 22943559 — intervention group
Group type: COMPARATOR
Intervention: Oral TDF (300 mg single exposure)
Number of subjects: 18
Study 22943559 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl cellulose (HEC) placebo gel
Number of subjects: 18
Study 16193473 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac patients
Number of subjects: 30
Study 16193473 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 11958408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass grafting material used in dental implants
Number of subjects: 17
Study 11958408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass grafting material
Number of subjects: 17
Study 10418907 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP//PRP‐T vaccine (group A, N = 85)
Number of subjects: 168
Study 10418907 — intervention group
Group type: COMPARATOR
Intervention: DTwP//Placebo vaccine (group B, N = 83)
Number of subjects: 168
Study 10418907 — intervention group
Group type: EXPERIMENTAL
Intervention: DT booster dose at age 5 years (subgroup A1)
Number of subjects: 168
Study 10418907 — intervention group
Group type: COMPARATOR
Intervention: DT booster dose at age 5 years (subgroup B1)
Number of subjects: 168
Study 10418907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib polysaccharide (PRP) vaccine (subgroups A2 and B2)
Number of subjects: 168
Study 7477984 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measures of functional capacity and neuropsychological performance
Number of subjects: 60
Study 7477984 — intervention group
Group type: EXPERIMENTAL
Intervention: CT indices of striatal atrophy
Number of subjects: 60
Study 7477984 — intervention group
Group type: EXPERIMENTAL
Intervention: CT index of frontal atrophy
Number of subjects: 60
Study 1705089 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin infusion via a four-way balloon catheter (5,000 U in 5 ml of saline)
Number of subjects: 89
Study 1705089 — intervention group
Group type: COMPARATOR
Intervention: Conventional three-way balloon catheter (control group)
Number of subjects: 89
Study 1705089 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin infusion group
Number of subjects: 89
Study 7287324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertex-negative external current
Number of subjects: 32
Study 7287324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertex-positive external current
Number of subjects: 32
Study 30870477 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentation algorithm for lumen contours and stent struts in OCT images
Number of subjects: 23
Study 30870477 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment algorithm for OCT pullbacks
Number of subjects: 23
Study 28424088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention alongside usual care
Number of subjects: 96
Study 28424088 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 96
Study 26687697 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (2400 mg/d; DHA: 1450 mg, EPA: 400 mg)
Number of subjects: 100
Study 26687697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23311957 — intervention group
Group type: EXPERIMENTAL
Intervention: IM olanzapine 10 mg
Number of subjects: 90
Study 23311957 — intervention group
Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 90
Study 21658014 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cmH(2)O)
Number of subjects: 32
Study 21658014 — intervention group
Group type: COMPARATOR
Intervention: ZEEP (0 cmH(2)O)
Number of subjects: 32
Study 18300861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 10
Study 18300861 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (control)
Number of subjects: 10
Study 18300861 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 15831596 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 395
Study 15831596 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 395
Study 12548300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild upper respiratory infection
Number of subjects: 138
Study 12548300 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pneumonia
Number of subjects: 138
Study 12548300 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-anemic children (control group)
Number of subjects: 138
Study 11205300 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 14
Study 11205300 — intervention group
Group type: COMPARATOR
Intervention: Control (historical)
Number of subjects: 14
Study 9322777 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 (mifepristone) and prostaglandin analogues
Number of subjects: 41
Study 7968336 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand mask technique
Number of subjects: 60
Study 7968336 — intervention group
Group type: COMPARATOR
Intervention: Manual ventilation through a face mask
Number of subjects: 60
Study 3777553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nifedipine (10 mg)
Number of subjects: 63
Study 3777553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.3 mg X kg‐1 followed by continuous infusion of 3 micrograms X kg‐1 X min‐1)
Number of subjects: 63
Study 3777553 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive treatment)
Number of subjects: 63
Study 28823192 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual removal of the placenta
Number of subjects: 574
Study 28823192 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous delivery of the placenta
Number of subjects: 574
Study 26902281 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day) plus Risperidone (up to 6 mg/day)
Number of subjects: 64
Study 26902281 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Risperidone (up to 6 mg/day)
Number of subjects: 64
Study 24979828 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 24979828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23326961 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 80
Study 23326961 — intervention group
Group type: COMPARATOR
Intervention: Current education
Number of subjects: 80
Study 20546155 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical pulmonary veins isolation (SURG)
Number of subjects: 22
Study 20546155 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency pulmonary veins isolation (RF)
Number of subjects: 22
Study 19013980 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose mitomycin C (MMC) administered to 49 patients
Number of subjects: 100
Study 19013980 — intervention group
Group type: COMPARATOR
Intervention: No mitomycin C administered to 51 patients
Number of subjects: 100
Study 16192524 — intervention group
Group type: EXPERIMENTAL
Intervention: Touchscreen desktop computer (kiosk)
Number of subjects: 366
Study 16192524 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held computer (PDA)
Number of subjects: 366
Study 16192524 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaire
Number of subjects: 366
Study 16192524 — intervention group
Group type: EXPERIMENTAL
Intervention: All study arms (including kiosk, PDA, and paper)
Number of subjects: 366
Study 16192524 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized arms (kiosk and PDA)
Number of subjects: 366
Study 16192524 — intervention group
Group type: COMPARATOR
Intervention: Paper arm
Number of subjects: 366
Study 12866362 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day for 3 months)
Number of subjects: 26
Study 12866362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study 10440415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 100 mg
Number of subjects: 22
Study 10440415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 200 mg
Number of subjects: 22
Study 10440415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 400 mg
Number of subjects: 22
Study 10440415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 22
Study 10440415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (400 mg, capsules and tablets)
Number of subjects: 22
Study 10440415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 400 mg and 600 mg
Number of subjects: 22
Study 10440415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22